Addition of a single E2 binding site to the human papillomavirus (HPV) type 16 long control region enhances killing of HPV positive cells via HPV E2 protein-regulated herpes simplex virus type 1 thymidine kinase-mediated suicide gene therapy

Human Gene Therapy
Rachna Sharma, Joel M Palefsky

Abstract

Human papillomavirus type 16 (HPV16) is associated with the development of anogenital cancers and their precursor lesions, intraepithelial neoplasia. Treatment strategies against HPV-induced intraepithelial neoplasia are not HPV specific and mostly consist of physical removal or ablation of lesions. We had previously designed an HPV-specific approach to kill HPV-infected cells by the herpes simplex virus type 1 thymidine kinase (TK) gene driven by HPV E2 binding to E2-binding sites (E2BS) in the native HPV16 long control region. E2-induced TK expression renders the cells sensitive to the prodrug ganciclovir. To optimize this therapeutic approach, we modified the native long control region by adding variable numbers of E2BS adjacent to E2BS4, resulting in greatly increased cell death in HPV-positive cell lines with variable levels of E2 protein expression and no reduction in HPV specificity. Our results showed maximum increase in TK expression and cell killing when one additional E2BS was added adjacent to E2BS. As HPV-infected patients also exhibit variable E2 expression across lesions and within a lesion, this approach may potentiate the clinical utility of the herpes simplex virus type 1 TK/ganciclovir therapeutic approach.

References

Jul 1, 1977·Journal of the National Cancer Institute·J FoghT Orfeo
Feb 1, 1992·Human Pathology·M H StolerT R Broker
Jul 1, 1988·Reviews of Infectious Diseases·T Matthews, R Boehme
Jul 1, 1995·Clinical & Experimental Metastasis·M A Turner, J M Palefsky
Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·M G Frattini, L A Laimins
Aug 1, 1994·Pharmacology & Therapeutics·C A Mullen
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·S Jeon, P F Lambert
Nov 14, 1997·The New England Journal of Medicine·M FrischM Melbye
Apr 3, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J M PalefskyT M Darragh
Aug 26, 1998·Journal of the National Cancer Institute. Monographs·J M Palefsky
Aug 26, 1998·Journal of the National Cancer Institute. Monographs·M Maiman
May 8, 1999·The Journal of Investigative Dermatology·D SawamuraI Hashimoto
Mar 11, 2000·Immunology·S M TodrykR G Vile
Apr 5, 2000·Molecular Pathology : MP·S A CordenA G Morris
Jun 10, 2004·Microbiology and Molecular Biology Reviews : MMBR·Michelle S Longworth, Laimonis A Laimins
Mar 9, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·John Doorbar
Nov 16, 2005·Reviews in Medical Virology·Christy M Hebner, Laimonis A Laimins
May 5, 2006·Journal of Clinical Microbiology·Hugo Arias-PulidoCosette M Wheeler
May 15, 2007·The New England Journal of Medicine·Suzanne M GarlandUNKNOWN Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators
Feb 3, 2009·Cellular and Molecular Life Sciences : CMLS·N Abdul HamidK Gaston
Feb 12, 2009·Genome Research·Agustin F FernandezManel Esteller
Nov 6, 2009·The New England Journal of Medicine·Gemma G KenterCornelis J M Melief

❮ Previous
Next ❯

Citations

Jul 26, 2011·Cellular & Molecular Biology Letters·Mandy S Y LungVincent Murray

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transfection

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.